{"name":"NextCure, Inc.","slug":"nextcure-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNTVc4OGFIcWFwMnJ1YXJSbXpLQm5oRU5PVXdrQnNJLVM0UE5fVmJvd3hKTUVmWDZZaTZqc2h5VlJ2dmpTcmUxNmdXR3Z1eHJTaXA2R2Vhal9FX0t4LXpwVG9qdEJqd3F2X183TVI3b2w5azR0MnlnZzdYMzFTb3FRTVRSdDVTOGFwR3VYUE95WHVBSjIxRWIyak14RXdvV0k1TklFcWtoc2UzVEZQeHZaLVFIcXU5UHlHWlhIcg?oc=5","date":"2026-04-07","type":"regulatory","source":"Stock Titan","summary":"FDA fast-tracks NextCure ovarian cancer drug ahead of ASCO data - Stock Titan","headline":"FDA fast-tracks NextCure ovarian cancer drug ahead of ASCO data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTFBXTGE3RFM5NWlhUGI5aG10S0hnZ3VSczRuY0hCU1hnX1RuRkU2ZFVHR0lnMXdtZDRBaG4zMW9GMjFadGlVUDFBWmJFVkgtQm53cTh2VTRYZGJiYllsMUdOZnNmb9IBY0FVX3lxTFBXTGE3RFM5NWlhUGI5aG10S0hnZ3VSczRuY0hCU1hnX1RuRkU2ZFVHR0lnMXdtZDRBaG4zMW9GMjFadGlVUDFBWmJFVkgtQm53cTh2VTRYZGJiYllsMUdOZnNmbw?oc=5","date":"2026-04-07","type":"pipeline","source":"Bitget","summary":"NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer - Bitget","headline":"NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNSThELUx3d0x6MkVPam9fMS10czk3bm10NXE4eG1lSmVicXV6a3pJUmpRUmNIc00xbjk2WGNod2lNaW5HODFjVzJTLWlGRTZJQTRRbnh1WFBfUUxCQW9OWWlkUWNQMTRnSDdKVHJvS2ZkVWNDVzlEd2dDTHMwblAyaW85V0p2WElsVUhYZ3UtdDliMFUxMW1vdzN3Z2dHdnhxRS1CYjNfZHQ5b2RDckVra3V2SC1XanlBd3JRX09BWQ?oc=5","date":"2026-03-31","type":"trial","source":"Stock Titan","summary":"Phase 1 cancer drug abstract lands ASCO 2026 slot in Chicago - Stock Titan","headline":"Phase 1 cancer drug abstract lands ASCO 2026 slot in Chicago","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-31","type":"pipeline","source":"The Manila Times","summary":"NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026 - The Manila Times","headline":"NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSmdlcTdfYjZkWGE1VjU3WjFOT0MySVJoUFAyUjlqUG82aHhKekhqZXRYZ0dUOUtpWXBxN3psYmRkUDRhcTRzOUpuM3VHaXVQcWdWVUdMbm1RUlV1SDc2TXdac3ZxTXhBak1YSnhMWXp4YzFyQk9HWExqOUpNam9wcEhEcUhTc3JwdDJBdnFzUHJWMmljeGkxbDNKVUcwWlhnYW1EMU0yYXEyeGZucUItYndpNXpleEl1d3U4?oc=5","date":"2026-03-14","type":"pipeline","source":"AD HOC NEWS","summary":"NextCure Inc Stock (ISIN: US65343E1082) Faces Analyst Downgrade Amid Biotech Sector Headwinds - AD HOC NEWS","headline":"NextCure Inc Stock (ISIN: US65343E1082) Faces Analyst Downgrade Amid Biotech Sector Headwinds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQUkJBSFcwbHFrdlJBUnduVE9WTEtJM3NvWjF3SkIwdENXd1A4b1dGcE9pY3N3M2piY1ctQUpyVXlOYk80dlQ1dlU4MVFqMDZ0V1NiUjdPTnZ3MndacHNoaWV5azdueGJ1Tzh3dk9JSWo2Z0hJWFlkRWpvellxbmo0Y2RPUXdpMjlCNi1OYUE0MEZFbW8?oc=5","date":"2026-02-05","type":"regulatory","source":"BioWorld News","summary":"Cancer index surges 72% as Terns, Olema lead gains - BioWorld News","headline":"Cancer index surges 72% as Terns, Olema lead gains","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNd0FqLWo3MmNCUmJ4MGo5SHZ0NnNRYXpuYU15UFNnM2Z2UndrNXB3VHlUMWtIUnl1QWFCUEVaYkJnQjJ0LUJXZndoX1ZpZnpkZVd0ZDNxSEVBUzRvS19lOUFxSTVZRkJCQ3hXT01Vb1pUV3N2ZzRWRzA5Ul94WktEYkI0eTN6TDlRckJFeFVESmdvVm81ZEpzcnYwNzc5OVdaNmZadUVyeGVNZExkUjEzdnpoejM?oc=5","date":"2025-11-13","type":"pipeline","source":"BioSpace","summary":"U.S. Antibody Drug Conjugates Market Set to Reach USD 11.70 Billion by 2034 - BioSpace","headline":"U.S. Antibody Drug Conjugates Market Set to Reach USD 11.70 Billion by 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxOZllWcHlOeTRXNThxb0phMlRpbWZmSkZGdTBKWS05NTJiTzlxNU9oQmJKZjZ6OUFXaURXZS1pMkV1S1RTOGpmd0hUWXM5Q05hazlrQ21CZVUzMG5tMWF5cUpVNGpOZG10dG5JVThfVkZxRUJteXBTZi1ETUZkaUgtWmdBb1RhTWt2RXhlVUJHbWFkS2lWcGcxZFVaU0wyRGFRQzBpTFZ6N1oyMjBqRGpFcF81VUJqS2JhaEhVU08yandXRjlWMlgyR09uZ18tU3kwZTE0V0NkMUVnbG9GUU9zLWpWQlRnQm13OG5zSTA2aHZ2U1JQZDI3dXktQ2txR3lTMzRnWDJFZWlYV2NVVHRB?oc=5","date":"2025-06-16","type":"deal","source":"GlobeNewswire","summary":"NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6 - GlobeNewswire","headline":"NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPVjJ6VXhteHJ2TXJBZ1FpNjlDNUw3cFgtY3QwMVlOMlcwa0pJcFRSODRWd3hCbTdMYXNRdHhpemltSHpoR2x1bDZGMjNvOHI4V01pTFBrMjYyWmsyLTRYdzdTN2ZxaEdFUUxvRGRaNkpHZkYxZHBkcFdBQ3I2NV95ci0tWFFnNVpRenJjUDE3cF94bWU2QU1R?oc=5","date":"2024-03-21","type":"pipeline","source":"BioPharma Dive","summary":"NextCure to lay off 37% of staff, dial back research plans - BioPharma Dive","headline":"NextCure to lay off 37% of staff, dial back research plans","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTFB1Z2s2TVI4ZDhxMG4yUG1yTGRVYURuaHMyQkxFVlB0SFF0SUhDb0h6OEo2aTIxbGs4a0VFeVJPbl9FUHpLSExzRGVfaHpqUWQ5YU5wZjFORFlLM09VTUlZNjhFcUk?oc=5","date":"2023-03-04","type":"pipeline","source":"GuruFocus","summary":"Timothy Mayer Net Worth (2026) - GuruFocus","headline":"Timothy Mayer Net Worth (2026)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNWlVGUk45b0t1cWdnVlZhZTVHaE5ySHlKX0tnSEtmM0U4ZEFkdU1Rdjc0dUdXUnFBdHk0VVN3X1ppZmd0bHdvUy1SaHlQbmpHMms2NDB0ZWk1MnlYQmh1dDE2bDdRc2NWU2pMLUJZUm9RbUZFLVd0WUlyMlA5R09rMVZ4V3d3NGtWR2lPa0hpN21UM1NOOWRMdUEwUUdqd18yUjh3OFJrU3k?oc=5","date":"2020-01-08","type":"pipeline","source":"statnews.com","summary":"A new biotechnology and pharmaceutical industry commitment to patients and the public - statnews.com","headline":"A new biotechnology and pharmaceutical industry commitment to patients and the public","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE8xUmdqdzZVR01SUjZLU1hoUmpOTE9zSlhMZ19uLTc4V25DeWhLeklNcHFGbUhRY3NjTVpjV2NWUDk5SEFDZ1MwV2g0RXNtdUhGLXdZRkZUclJkYzZ2?oc=5","date":"2019-05-10","type":"pipeline","source":"TradingView","summary":"NXTC Stock Price and Chart — NASDAQ:NXTC - TradingView","headline":"NXTC Stock Price and Chart — NASDAQ:NXTC","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}